415 related articles for article (PubMed ID: 32387389)
1. Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19).
Khodadadi E; Maroufi P; Khodadadi E; Esposito I; Ganbarov K; Espsoito S; Yousefi M; Zeinalzadeh E; Kafil HS
Microb Pathog; 2020 Sep; 146():104241. PubMed ID: 32387389
[TBL] [Abstract][Full Text] [Related]
2. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking.
Joshi T; Joshi T; Sharma P; Mathpal S; Pundir H; Bhatt V; Chandra S
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4529-4536. PubMed ID: 32373991
[TBL] [Abstract][Full Text] [Related]
3. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
Molecules; 2020 May; 25(11):. PubMed ID: 32485894
[TBL] [Abstract][Full Text] [Related]
4. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2.
Panda PK; Arul MN; Patel P; Verma SK; Luo W; Rubahn HG; Mishra YK; Suar M; Ahuja R
Sci Adv; 2020 Jul; 6(28):eabb8097. PubMed ID: 32691011
[TBL] [Abstract][Full Text] [Related]
5. Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2.
Zhang Y; Kutateladze TG
Nat Commun; 2020 Jun; 11(1):2920. PubMed ID: 32523109
[TBL] [Abstract][Full Text] [Related]
6. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
Sternberg A; McKee DL; Naujokat C
Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
[TBL] [Abstract][Full Text] [Related]
7. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
8. [Source of the COVID-19 pandemic: ecology and genetics of coronaviruses (Betacoronavirus: Coronaviridae) SARS-CoV, SARS-CoV-2 (subgenus Sarbecovirus), and MERS-CoV (subgenus Merbecovirus).].
Lvov DK; Alkhovsky SV
Vopr Virusol; 2020; 65(2):62-70. PubMed ID: 32515561
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
Anand P; Puranik A; Aravamudan M; Venkatakrishnan AJ; Soundararajan V
Elife; 2020 May; 9():. PubMed ID: 32452762
[TBL] [Abstract][Full Text] [Related]
10. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
12. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes.
Kandeel M; Ibrahim A; Fayez M; Al-Nazawi M
J Med Virol; 2020 Jun; 92(6):660-666. PubMed ID: 32159237
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin converting enzyme-2 as therapeutic target in COVID-19.
Roshanravan N; Ghaffari S; Hedayati M
Diabetes Metab Syndr; 2020; 14(4):637-639. PubMed ID: 32428864
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
15. COVID-19: a conundrum to decipher.
Deshmukh V; Tripathi SC; Pandey A; Deshmukh V; Vykoukal J; Patil A; Sontakke B
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5830-5841. PubMed ID: 32495923
[TBL] [Abstract][Full Text] [Related]
16. Fighting the Coronavirus Outbreak.
Kiessling L; Chen P; Wang J; Li JP
ACS Chem Biol; 2020 Apr; 15(4):799-801. PubMed ID: 32233418
[No Abstract] [Full Text] [Related]
17. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
18. Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.
Sturley SL; Rajakumar T; Hammond N; Higaki K; Márka Z; Márka S; Munkacsi AB
J Lipid Res; 2020 Jul; 61(7):972-982. PubMed ID: 32457038
[TBL] [Abstract][Full Text] [Related]
19. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
20. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]